Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Uveal melanoma (UM) is the most common primary intraocular malignancy and a leading cause of melanoma-related deaths.
• Despite its rarity, metastatic UM has a poor prognosis, with limited therapeutic advancements.
• While TP53 mutations are infrequent in UM, the p53 pathway is often dysfunctional, impacting DNA damage responses.

Purpose of the Study:

• To investigate p53 protein functionality and downstream target activation in UM cell lines under standard treatments.
• To explore the role of p53 isoforms in UM pathogenesis and response to therapy.
• To correlate p53 isoform expression with clinical outcomes in UM patients.

Main Methods:

• Analysis of p53 protein stabilization and target gene activation in UM cell lines treated with cisplatin and proton-beam irradiation.
• Characterization of p53 isoform expression profiles in UM cell lines and patient samples.
• Functional studies involving the down-regulation of short p53 isoforms to assess their impact on cell growth and death.
• Correlation analysis between p53 isoform expression levels and clinicopathological features in 32 UM cases.

Main Results:

• Most UM cell lines retained wild-type p53, but exhibited variable p53 protein stabilization and target activation.
• UM cells express a diverse range of p53 isoforms, including short variants like Δ160p53α and Δ133p53β, and longer variants like Δ40p53β and p53β.
• Down-regulation of short p53 isoforms (Δ133/Δ160) enhanced cell proliferation and reduced therapy-induced cell death.
• Higher expression of Δ40p53α or Δ133p53γ isoforms correlated with more aggressive UM cancers.

Conclusions:

• Short p53 isoforms can drive UM cell growth and confer resistance to standard therapies.
• Specific p53 isoforms (Δ40p53α, Δ133p53γ) are associated with increased UM aggressiveness.
• Targeting short p53 isoforms may represent a novel therapeutic strategy for UM.
• These findings provide critical insights into the molecular mechanisms underlying UM progression and treatment resistance.